THE LEADING RESEARCH REPORTS DISTRIBUTION
NETWORK

icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research icrowd research

Genome Editing Market Size Worth $23 Billion By 2030 : IndustryARC

Oct 4, 2023 12:00 AM ET

Genome Editing Market Size Worth $23 Billion By 2030 : IndustryARC

Genome Editing Market Size is Predicted to Reach $23 Billion by 2030g, growing at a CAGR of 19.2 % during the forecast Period 2023-2030 according to the latest market research report published by IndustryARC. The streaming demand for synthetic genes and personalised medicine and increase in the infectious diseases like Cancer are poised to propel the market growth, finds IndustryARC in its recent report, titled “Genome Editing Market Size, Share & Trends Analysis [By Product and Service Type (reagents and consumables, software and systems, services) By Technology (Restriction Enzymes, Zinc-Finger Nucleases (ZFN), transcription activator-like effector nucleases (TALEN), Clustered regularly interspaced short palindromic repeats (CRISPR), Antisense and Others) By Application(Animal Genetic Engineering, Plant Genetic Engineering, Drug Discovery and Development, Diagnostic applications, Cell Line Engineering, Others) By End User(biotech and pharma companies, Government and Academic Research Institutes, contract research organizations) By Delivery Method( Ex- vivo, In- vivo) By Mode( Contract, In- house) By Geography – Global Opportunity Analysis & Industry Forecast, 2023-2030].

Request Sample Research Report:

https://www.industryarc.com/pdfdownload.php?id=509619

North America Contributes with Largest Market Share:

North America Genome Editing Market held the largest share in 2022 contributing with more than 40% of the total market revenue. It is mainly owing to its use in various end varieties of crops to modify the crops to yield better results. Additionally, the region’s predominant position in local infrastructure pertaining to giant bio-pharma companies. The leading genome editing companies in the region are also focussed on continuously conducting experiments in introducing new drugs for various life threating genetic disorders including Hereditary angioedema.  In March 2023, INTELLIA Therapeutics, Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s investigational new drug application TLA-2002 for the treatment of hereditary angioedema (HAE), . This will help the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study.

Genome Editing Market 2023-2030: Segmentation

By Product and Service Type

Reagents and Consumables

Software and Systems

Services

By Technology

Restriction Enzymes

Zinc-Finger Nucleases (ZFN)

Transcription activator-like effector nucleases (TALEN)

Clustered regularly interspaced short palindromic repeats (CRISPR)

Antisense

Others

By Delivery Method

Ex- vivo

In- vivo

By Mode

Contract

In-house

By Application

Animal Genetic Engineering

Plant Genetic Engineering

Drug Discovery and Development

Diagnostic Applications

Cell Line Engineering

Other

By End-User

Biotech and Pharma Companies

Government and Academic Research Institutes

Contract Research Organizations (CRO’s)

By Geography

North America (U.S., Canada and Mexico and Rest of North America)

Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

LAMEA (Saudi Arab, Brazil, Qatar, Argentina, South Africa, Nigeria, UAE and Rest of LAMEA)

Rest of the World (Middle East and Africa).

By companies profiled

Thermo Fisher Scientific,Inc.

Merck KGaA

Integrated DNA Technologies, Inc.

New England Biolabs, Inc.

Sangamo Biosciences, Inc.

GenScript (China) 

Agilent Technologies, Inc.

Creative Biogene

IntelliaTherapeutics, Inc.

Lonza Group

Horizon Discovery Ltd.

Tecan Genomics, Inc.

Synthego Corp.

Bean Therapeutics, Inc

Bluebird Bio, Inc.

 

Get Access to Full Research Report:

https://www.industryarc.com/Research/Genome-Editing-Market-Research-509619

Genome Editing Market Report – Key Takeaways:

CRISPR Technology is Leading the Market, TALEN is Fastest Growing

CRISPR and CRISPER-Cas9 is an immune defense system to edit the DNA and has redefined the approach to gene therapy across the globe owing to their simplicity and being a more efficient alternative to specific gene editing. This technology is the largest revenue contributor in the genome editing market and is estimated to grow with a double digit CAGR during the forecast period 2023-2030. On the other hand, TALEN technology is witnessed to be growing at the fastest CAGR of 20.3% during the period under study. The major factors behind the fastest growth of TALEN technique is its specificity, versatility and accessibility. It can be used to edit a wide range of organisms including bacteria and plants and can be used for any type of DNA mutation such as substitutions, insertions and deletions.

Asia Pacific Region Grows Fastest, Development of Gene-editing Policies in Many Countries

Asia Pacific market for genome editing is growing fastest during the forecast period 2023-2030. Many regional countries such as Japan, India, Philippines, Vietnam, Indonesia are setting, revising or are coming up with clear guidelines for the use of genome editing tools. Japan has commercialized the gene-edited products and has implemented clear guidelines whereas, in India, Department of Biotechnology has introduced a new set of guidelines for genome editing in 2022, to ensure the safety of environment and organisms under its Environment Protection Act.

Purchase this Premium Report:

https://www.industryarc.com/purchasereport.php?id=509619

Key Opportunity Analysis:

Reduction in Breeding Time through Gene-editing offers Large Opportunities in Agriculture Sector

Gene editing leads to reduced breeding time in the produce any new variety of plants and also reduce the expenses for research and development. This technique offers an opportunity to address a range of difficulties associated with developing durable resistances to ailments, pests and abiotic stresses It also has the potential to reduce costs of crop protection and decrease labour demand. Regulators of different counties have been involved in considering the process to manage gene-edited products in agrifood systems over a decade.  For example, in 2022, Health Canada published a scientific opinion on the regulation of gene-edited plant products which stated that novel food products from any breeding technique that might represent a food safety hazard would require a food safety assessment, to be done according to domestic guidance.

Gene-editing Increasingly Gaining Momentum in Europe, Seeking Relaxation of Rules

Countries such as UK announced to relax rules and regulations for research on genetically engineered crops. Agriculture ministers in EU also agreed to relax rules on GMOs and the use of new precision techniques which can make the modification of a plant’s DNA at a faster pace and can result in strengthening the food sector in EU.  According to the European Commission, the EU has spent €685.5 million on bioeconomy-oriented research related to NGTs, including €271 million for plant biotechnology research in the past decade. Companies can tap the market potential in Europe region and come up

If you have any questions, please feel free to contact our experts at:

https://www.industryarc.com/reports/request-quote?id=509619

The Report also Covers the Following Areas:

  • Genome Editing Market Size and Forecast.
  • Genome Editing Market Trends.
  • Genome Editing Market Analysis by Technologies.

 

Genome Editing Market 2023-2030: Key Highlights

  • CAGR of the Market During the Forecast Period 2023-2030.
  • Value Chain Analysis of Key Stake Holders.
  • Detailed Analysis of Market Drivers and Opportunities During the Forecast Period.
  • Genome Editing Market Size Estimation and Forecast.
  • Analysis and Predictions on End Users Behaviour and Upcoming Trends.
  • Competitive Landscape and Vendor Market Analysis including offerings, Developments and Financials.
  • Comprehensive Analysis of Challenges and Constraints in the Genome Editing Market.

 

COVID-19 / Ukraine Crisis – Impact Analysis:  Key Takeaways:

  • Due to the global economic crisis caused by the covid, it disrupted many known healthcare sectors across the world. It even has moderate effect on several healthcare services including the genome editing market. But COVID-19 has boosted up the growth of genome editing market as gene editing tool is taken foremost during the pandemic. Furthermore, as COVID-19 is a virus that naturally occurred due to the bacteria, gene editing system plays a key role in the defence against the viral infections.
  • The Ukraine-Russia conflict has demonstrated the negative impact on genome editing due to increase in the cost of supply chains. Most of the gene editing markets are associating with the United States for gene edited products to differentiate current methodology from older genetically modified Organism Technology that Invoked Consumers, Retailers and Farmers Negatively.

 

To Get a Customized Industry Analysis, Speak with our Research Analyst:

https://connect.industryarc.com/lite/schedule-a-call-with-our-sales-expert

List of Key Market Players in Genome Editing Market:

The top 10 companies in this Industry are listed below:

  1. Thermo Fisher Scientific,Inc.
  2. Merck KGaA
  3. Integrated DNA Technologies, Inc.
  4. New England Biolabs, Inc.
  5. Sangamo Biosciences, Inc.
  6. GenScript (China)
  7. Agilent Technologies, Inc.
  8. Creative Biogene
  9. IntelliaTherapeutics, Inc.
  10. Lonza Group

Related Reports:

Injectable Drug Delivery Market – The Injectable Drug Delivery market is Projected to Grow at a CAGR of 11.8% During the Forecast Period from 2023 to 2030. Increase in Number of Needle Injuries, Chronic Diseases and Worldwide Usage of Injections Increasing Its Growth Rate.

Lateral Flow Assays Market – Lateral Flow Assays Market size is Growing at a CAGR of 4.4% During the Forecast Period. It is Due to the Increasing Growth of Rapidly Increasing Population, High Infectious Disease Globally, Rising Demand for POC devices, Increasing use of Home-Based Assay Devices.

Oncology Drugs Market – The Oncology Drugs Market is Growing at a CAGR of 11.6% During the Forecast Period. It is Due to the Rise Increased Use of Tobacco, Advancement in Treatment Types and an Increasing Number of Cancer Cases.

About IndustryARC™:

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets. 

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

 

Contact Us:

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA: (+1) 518-282-4727

Web: https://www.industryarc.com

Follow us on: LinkedIn | Facebook | Twitter

Tags: , , ,

See Campaign: https://www.industryarc.com

Contact Information:

Mr. Venkat Reddy IndustryARC Email: [email protected] USA: (+1) 518-282-4727



Tags:

Wire, Extended Distribution, iCN Internal Distribution, BNN, Research Newswire, English